SYR-472 Open-label Study

This study has been completed.
Information provided by (Responsible Party):
Takeda Identifier:
First received: December 13, 2012
Last updated: November 5, 2013
Last verified: November 2013

To evaluate the efficacy and safety of treatment with SYR-472 in diabetic patients.

Condition Intervention Phase
Diabetes Mellitus
Drug: SYR-472
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Takeda:

Primary Outcome Measures:
  • Blood Glucose [ Time Frame: 7 days ] [ Designated as safety issue: No ]
    Blood Glucose

Enrollment: 14
Study Start Date: April 2013
Study Completion Date: August 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SYR-472 100mg
SYR-472 100mg
Drug: SYR-472


Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

-1. The participant is judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator.

2. The participant can sign and date a written, informed consent form prior to the initiation of any study procedures.

Exclusion Criteria:

-1. The participant has concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease

. 2. The participant is assessed to be ineligible for the study by the investigator or subinvestigator.

  Contacts and Locations
Please refer to this study by its identifier: NCT01751360

Suita-shi, Osaka, Japan
Sponsors and Collaborators
Study Director: General Manager Takeda
  More Information

No publications provided

Responsible Party: Takeda Identifier: NCT01751360     History of Changes
Other Study ID Numbers: SYR-472/OCT-002, U1111-1137-2768, JapicCTI-122024
Study First Received: December 13, 2012
Last Updated: November 5, 2013
Health Authority: Japan: Ministry of Health, Labor and Welfare

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases processed this record on April 23, 2014